Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences: Psychiatry

Prediction of cognitive and metabolic changes after acute antidopaminergic treatment measured by FDOPA PET

Ingo Vernaleken, Yoshitaka Kumakura, Hans-Georg Buchholz, Thomas Siessmeier, Peter Bartenstein, Paul Cumming and Gerhard Gründer
Journal of Nuclear Medicine May 2007, 48 (supplement 2) 263P;
Ingo Vernaleken
1Department of Psychiatry, RWTH Aachen University, Aachen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshitaka Kumakura
2University of Tokyo, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Georg Buchholz
3University of Mainz, Mainz, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Siessmeier
3University of Mainz, Mainz, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bartenstein
4Ludwig Maximilian Universität, München, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Cumming
5Aarhus University, Aarhus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard Gründer
1Department of Psychiatry, RWTH Aachen University, Aachen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1199

Objectives: In previous PET studies the net influx of 6-[18F]-fluorodopa (FDOPA) correlated with cognitive performance in normal subjects. Furthermore, acute D2-antagonistic treatment elevated the FDOPA net influx by autoreceptor regulation. Using now an improved method of graphical analysis, diffusion of FDOPA metabolites can be unmasked and the total distribution volume of FDOPA and its acidic metabolites (VD) can be measured reflecting the dopamine storage capacity (Kumakura et al. 2005). The present study tested whether metabolic changes under acute antipsychotic treatment could predict changes in cognition. Methods: Nine healthy drug-free volunteers were scanned using FDOPA-PET. They performed cognitive tasks directly before the PET scans (TMT-A/B, Stroop, WCST, ds-CPT). They performed two scans, before and after three days of haloperidol treatment (5mg/day). The net blood-brain clearance of FDOPA (K) in striatum, the rate of diffusion of acidic metabolites from brain (kloss) and VD were calculated in striatal and extrastriatal regions. Results: K values showed an increase after haloperidol treatment similar to those previously observed using the conventional method of Martin et al. (1989). VD and kloss showed no significant changes after haloperidol treatment. However, the CPT performance was significantly and negatively correlated with the baseline K in the putamen and amygdala (NC: r = -678; P = 0.045 / amygdala: -0.862; P = 0.003). Furthermore, the change in kloss and the change in VD significantly correlated in NC with baseline K (kloss: r=+0.881; P=0.002; VD: -0.905; P<0.001). Conclusions: Under short treatment with a D2-like receptor antagonist low baseline net blood-brain FDOPA uptake (K) predicts an increase of dopamine storage capacity (VD) whereas high initial K values in principle led to decreased storage capacities. This is mainly caused by reciprocal changes in kloss. Furthermore a high baseline K predicts an impairment of CPT performance whereas low K values interestingly predict an improvement in CPT performance. These results help to understand the dopaminergic control of cognition.

  • Society of Nuclear Medicine, Inc.
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 48, Issue supplement 2
May 1, 2007
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prediction of cognitive and metabolic changes after acute antidopaminergic treatment measured by FDOPA PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Prediction of cognitive and metabolic changes after acute antidopaminergic treatment measured by FDOPA PET
Ingo Vernaleken, Yoshitaka Kumakura, Hans-Georg Buchholz, Thomas Siessmeier, Peter Bartenstein, Paul Cumming, Gerhard Gründer
Journal of Nuclear Medicine May 2007, 48 (supplement 2) 263P;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prediction of cognitive and metabolic changes after acute antidopaminergic treatment measured by FDOPA PET
Ingo Vernaleken, Yoshitaka Kumakura, Hans-Georg Buchholz, Thomas Siessmeier, Peter Bartenstein, Paul Cumming, Gerhard Gründer
Journal of Nuclear Medicine May 2007, 48 (supplement 2) 263P;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences: Psychiatry

  • SPECT evaluation of regional cerebral blood flow in major depressive disorder: Effect of therapy and relationship with endothelial dysfunction markers
  • Brain glucose metabolism changes following thyroid function normalization in hyperthyroidism
  • Thalamic glucose metabolism matched with ultra high resolution anatomy and tractography obtained by PET-MRI fusion imaging
Show more Neurosciences: Psychiatry

Psychiatry Posters

  • Perfusion and DAT analysis for depressive mood in drug naïve PD patients using dual phase F-18 FP-CIT PET
  • Brain SPECT as Imaging Biomarker for Evaluating Effects of Novel Treatments in Psychiatry.
  • Regional homogeneity and FDG uptake in patients with major depressive disorder
Show more Psychiatry Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire